HC Wainwright Has Positive Forecast for AURA FY2024 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities research analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Aura Biosciences in a report released on Wednesday, November 13th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($1.69) for the year, up from their prior estimate of ($1.71). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2025 earnings at ($1.94) EPS and FY2026 earnings at ($2.06) EPS.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02.

AURA has been the subject of several other research reports. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. BTIG Research raised their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, JMP Securities raised their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Aura Biosciences has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Down 3.5 %

Shares of AURA opened at $9.14 on Monday. The stock has a market cap of $456.54 million, a PE ratio of -5.28 and a beta of 0.33. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The business has a 50-day simple moving average of $9.82 and a two-hundred day simple moving average of $8.54.

Institutional Trading of Aura Biosciences

Several large investors have recently made changes to their positions in the company. American International Group Inc. lifted its holdings in shares of Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares in the last quarter. Levin Capital Strategies L.P. raised its holdings in Aura Biosciences by 11.2% during the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock worth $873,000 after buying an additional 11,200 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Aura Biosciences in the first quarter valued at $144,000. Bank of New York Mellon Corp lifted its stake in shares of Aura Biosciences by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after buying an additional 48,549 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Aura Biosciences

In other news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares in the company, valued at $1,615,340.28. The trade was a 15.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO Mark Plavsic sold 7,383 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at approximately $1,193,150.20. This represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,081 shares of company stock worth $891,353 over the last three months. 5.40% of the stock is owned by company insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.